HUTCHMED (China) Limited ( (HK:0013) ) has issued an announcement.
HUTCHMED (China) Limited announced that the ordinary resolution proposed at its Extraordinary General Meeting on March 31, 2025, was passed. This resolution involves the sale and purchase of a 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited, which was overwhelmingly supported by shareholders. This decision could significantly impact the company’s strategic operations and market positioning by potentially streamlining its focus and resources.
More about HUTCHMED (China) Limited
HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company focused on the discovery, global development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company has successfully marketed its first three medicines in China, with one also approved in the US, Europe, and Japan.
YTD Price Performance: 0.85%
Average Trading Volume: 45,758
Technical Sentiment Signal: Buy
Current Market Cap: £2.11B
For an in-depth examination of 0013 stock, go to TipRanks’ Stock Analysis page.